Fintel reports that on February 24, 2025, Guggenheim initiated coverage of Compass Therapeutics (NasdaqCM:CMPX) with a Buy recommendation. Analyst Price Forecast Suggests 266.05% Upside As of February ...
Signing nine players in the last two off-seasons and all promised nine figures! The post "Doing What the System Allows": Rob ...
Solid U.S. growth and moderate inflation should support credit markets in 2025, creating a stable environment for high yield bonds and leveraged loans. Historically elevated yield levels are likely to ...